Rice Hall James & Associates LLC Purchases 309,518 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Rice Hall James & Associates LLC raised its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 579.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 362,893 shares of the company's stock after buying an additional 309,518 shares during the period. Rice Hall James & Associates LLC owned about 0.44% of Viridian Therapeutics worth $4,892,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in VRDN. FMR LLC increased its holdings in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock worth $227,776,000 after buying an additional 698,434 shares during the last quarter. Vanguard Group Inc. increased its holdings in Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares during the last quarter. Deep Track Capital LP increased its holdings in Viridian Therapeutics by 20.6% during the fourth quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock worth $86,701,000 after buying an additional 771,796 shares during the last quarter. Tang Capital Management LLC increased its holdings in Viridian Therapeutics by 11.1% during the fourth quarter. Tang Capital Management LLC now owns 2,492,925 shares of the company's stock worth $47,789,000 after buying an additional 250,000 shares during the last quarter. Finally, Alliancebernstein L.P. increased its holdings in Viridian Therapeutics by 3.8% during the fourth quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after buying an additional 84,255 shares during the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. HC Wainwright restated a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Needham & Company LLC reiterated a "buy" rating and issued a $36.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, May 20th. The Goldman Sachs Group reduced their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. JMP Securities reduced their target price on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Finally, Royal Bank Of Canada reduced their target price on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, Viridian Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $37.56.

Viridian Therapeutics Price Performance

VRDN stock traded up $0.53 during midday trading on Wednesday, reaching $16.79. The company had a trading volume of 418,673 shares, compared to its average volume of 1,146,170. The company has a market capitalization of $1.37 billion, a P/E ratio of -4.36 and a beta of 0.39. The company has a debt-to-equity ratio of 0.05, a current ratio of 19.49 and a quick ratio of 19.49. Viridian Therapeutics, Inc. has a 1 year low of $9.90 and a 1 year high of $27.20. The firm has a 50-day moving average price of $14.54 and a 200-day moving average price of $15.40.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) earnings per share for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.16 million. Viridian Therapeutics had a negative net margin of 102,092.39% and a negative return on equity of 70.61%. The firm's revenue was up .0% on a year-over-year basis. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.